Product Brochures

Plasma pTau181 — Simoa® technology enables breakthrough research.


In late 2021, Quanterix announced that its Simoa® phospho-Tau 181 (pTau181) blood test was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). A distinction not shared by any other company.